Background. Diabetes mellitus (DM) is a metabolic disorder syndrome that marked by hyperglycemia. The main macrovascular complication is heart failure due to diabetic cardiomyopathy. Hyperglycemia can increase reactive oxygen species (ROS) and lipid peroxidation that induce cellular damage. Quercetin is an antioxidant that reduce hyperglycemia and ROS by modify the expression of nuclear factor erythroid 2-related factor 2 (Nrf 2). Objective. The aim of this research was to investigate the effect of combination of quercetin and glibenclamide on myocardial nuclear factor erythroid 2-related factor 2 (nrf 2) expression in type 2 diabetic rat compared with no combination. Methods. The rats were divided randomly into nine groups (each group consisted of four rats). The control group consist of a normal group that received placebo, DM control groups that received placebo and glibenclamide and intervention groups received quercetin 5, 20 and 80 mg/kgbw/day and combination of quercetin with 5 mg/kgbw/day of glibenclamide orally for a period of four weeks. The expression of myocardial Nrf 2 was measured by immunohistochemistry. Data was analyzed by ANOVA and p<0.05 was considered as significant. Results. Twenty and 80 mg/kgbw/day of quercetin with or without combination with glibenclamide orally for a period of four weeks increase myocardial Nrf2 expression higher than placebo (p<0.05). Eighty mg/kgbw/day of quercetin increase myocardial Nrf2 expression higher than 5 and 20 mg/kgbw/day (p<0.05). Conclusion. From this study it can be suggested that there are significant different in expression level of myocardial Nrf2 of type 2 DM after a combination of quercetin and glibenclamide, quercetin alone, glibenclamide alone and placebo.
Background
Diabetes mellitus (DM) is a metabolic disorders syndrome that marked by chronic hyperglycemia, caused by defect in insulin secretion, insulin work or both that cause carbohydrate, protein and lipid metabolic disorders 1 . Diabetes mellitus is an uncurable disease. In 2005, about 135 million peoples in the world (about 3%) suffered from DM 2 . Its prevalence in the world can raise to 522 million peoples in 2030 3 . Data from National Institutes of Health (NIH), about 90-95% DM is type 2 DM 4 . In Indonesia, there was about 8.4 million peoples suffered from DM and the number will raises to 21.3 million people in 2030 5 . Diabetes mellitus complication is the main cause of its mortality. Chronic hyperglycemia is the main cause of microvascular complication like retinopathy, neuropathy, nefropathy and macrovascular complication especially cardiomyopathy. Hyperglycemia causes pathologic oxidant, raising lipid peroxidation and reactive oxygen species (ROS) which increase oxidative stress 6 . Reducing the amount of reactive oxygen species is the main strategy to prevent the DM complications. Antioxidant, for example superoxide dismutase (SOD), can reduces reactive oxygen species by pathologic oxidant scavenging. Antioxidant production mainly induced by nuclear factor erythroid 2-related factor 2 (Nrf2) system which activated by oxidative stress. The active Nrf2 can induce antioxidant response element (ARE) which stimulate transcription of genes that encodes antioxidant enzyme production like SOD, heme oxygenase (HO-1), catalase, glutathione S-transferase (GST) and NAD(P)H:quinone oxidoreductase-1 (NQO1) 7 . In recent years, various type of antioxidant including flavonoid were used for the management of DM. Quercetin is one of flavonoid antioxidant which raise Nrf2 expression and also can reduces lipid peroxidation 8 . The groups consist of a normal group and 8 DM groups. Rats in a DM group were induced with streptozotocin (STZ) of 60 mg/kgbw intraperitoneally. After 15 minutes, rats were injected with nicotinamide of 120 mg/kgbw intraperitoneally. A week later, fasting blood glucose was measured . Rats with fasting blood glucose level more than 126 mg/dL were included as type 2 diabetic 9 . Quercetin and glibenclamide were administered orally for a period of 4 weeks. After 4 weeks, all rats were decapitated. Fasting blood glucose level was measured with GOD-PAP method before administration of quercetin, glibenclamide or the both combination (pretest) and before decapitation (posttest). The expression of Nrf2 was examined with immunohistochemistry (IHC).
Methods

Measuring fasting blood glucose level with GOD-PAP method
Blood withdrawn from sinus orbitalis. Rats fasting for a period of 12 hours before examination. As many as 10 µL blank (aquabidest), sample and standart was put into tubes then added with 1000 µL of glucose kit solution. Then the solution was incubated for a period of 10 minutes at 37˚ C. The absorbance was determined at 500 nm wave length.
Measuring myocardial Nrf2 expression with immunohistochemistry (IHC)
The heart tissue was fixed with formaline buffer. Then paraffin block was made on vertical slice. Myocardial Nrf2 expression was measured with immunohistochemistry. Positive Nrf2 expression was shown with brown colour in the nucleus and negative Nrf2 expression was shown with blue colour in the nucleus. Percentage of Nrf2 expression was calculated by the ratio of positive cells that expressed Nrf2 in the nucleus and total of cells.
Result analysis
Myocardial Nrf2 expression was analysed with One Way ANOVA if it was normally distributed or with Kruskal-Wallis ANOVA if it was not normally distributed.
Result and discussion
Characteristic of the research subject Rats Weight
Weight data between groups at pretest and posttest measurements were analyzed by One Way ANOVA test. The weight was not significantly different between groups (p> 0.05) on the pretest and posttest measurements. Then, the difference between pretest to posttest was analyzed using a paired t test for each group. The mean of body weight of rats decreased significantly at posttest measurements in groups of K5 and K9, but not significantly in the group K2, K3, K6, K7 and K8. The mean body weight was not significantly increase in the group K1 and K4. Table 2 shows the mean body weight of rats at pretest and posttest measurements. . Weight loss in rats fed with quercetin may be caused by the effects of quercetin itself. Based on previous studies 20 to 625 mg / kgbw / day orally of quercetin given for 8 weeks resulted in significant weight loss due to the ability of quercetin in increasing lipolysis, increasing fatty acid oxidation and decrease adipogenesis 11 . Fasting blood glucose level Differences in fasting blood glucose (FBG) level between the groups were analyzed using nonparametric test of Kruskal-Wallis. There were at least two groups that have significant different of FBG level (p <0.05) at pretest and posttest measurements. Then post hoc analyzes was performed using the Mann-Whitney test. There was a significant different of FBG level between K1 and K2 to K9 groups at pretest and posttest measurements. Differences in FBG level between rats in each group at pretest and posttest measurements were tested using the paired t test. There was a significant decrease of FBG level in K1 group. There was no significant decrease in mean FBG level of K4 and K7 groups. There was no significant increase of mean FBG level in the K2, K3, K5, K6, K8 and K9 groups. Large variations in FBG level between groups was likely due to the differences in induction period. This causes unequal distribution of rats between group. In addition, there is a difference period of time to become diabetic rats. There were rats that meet the criteria of DM (FBG> 126 mg / dL) at 1 week ,others meet the criteria of DM after 3 weeks post-induction. Table 3 shows the mean of FBG level at pretest and posttest measurements.
Increase FBG in rats fed with quercetin and or glibenclamide in this study occurred in the group that need longer period of induction. These rats had longer experience of diabetes so the pancreas was more severely damage. Based on previous study, quercetin can lower FBG level in people with diabetes. Ten mg / kgbw / day and 15 mg / kgbw / day orally of quercetin for 10 days can lower fasting blood glucose level significantly, improve glucose tolerance test value and helps regenerate pancreatic beta cells. Quercetin has the ability to increase glucokinase enzyme activity in the Positive expression of nuclear factor erythroid 2-related factor 2 (Nrf2) in rat myocardial is shown as brown color, whereas negative expression is shown as blue color in the cell nucleus. Immunohistochemistry image of the myocardial which expressed Nrf2 on cell nucleus and which are not is shown in Figure 1. a= the myocardial which not expressed Nrf2 in cell nucleus, b= the myocardial which expressed Nrf2 in cell nucleus Figure 1 . Immunohistochemistry image of the myocardial which expressed Nrf2 in cell nucleus and which are not In the calculation of percentage of myocardial Nrf2, expression K1 group was the lowest whereas K9 group was the highest percentage . There was significant different of myocardial Nrf2 expression between groups (p <0.05). Post-hoc test showed the significant different between K1 and K2 to K9 groups. Table 4 shows the mean percentage of myocardial Nrf2 expression. There was an increase in expression of myocardial Nrf2 significantly in the rat groups were induced into DM when compared with the normal group. Type 2 DM is characterized by chronic hyperglycemia, lead to an increase in free radicals and oxidative stress more than normal conditions that induced an increase in the release of Nrf2 from Keap1 protein in the cytoplasm. The Nrf2 will translocate to the nucleus so that Nrf2 expression increased in cell nucleus 13 . In this study, rats that received 80 mg / kgbw / day of quercetin have the highest increases in cardiac muscle Nrf2 expression when compared with that of the groups received placebo, glibenclamide , 5 and 20 mg / kgbw / day of quercetin. Giving glibenclamide in combination with quercetin had no effect in increasing myocardial Nrf2 expression compared with that of quercetin alone. Previous studies showed that the dose of quercetin affect its ability to reduce oxidative stress in DM rat 14 . Conclusion From this study it can be suggested that there are significant different in expression level of myocardial Nrf2 of type 2 DM after received a combination of quercetin and glibenclamide, quercetin alone, glibenclamide alone and placebo.
